MedTrace Logo

Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions

NCT00652795 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-04-04

No results posted yet for this study

Summary

To compare the rate and extent of absorption of doxycycline tablet (Par) versus doxycycline capsule (Monodox)(Oclassen).

Conditions

  • To Determine Bioequivalence Under Fasting Conditions

Interventions

DRUG

Doxycycline Monohydrate

Tablets, 150 mg, single-dose

DRUG

Monodox

Capsules 50 mg (3 x 50 mg dose), single-dose

Sponsors & Collaborators

  • Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Benoit Girard, M.D. · Anapharm

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652795 on ClinicalTrials.gov